에 대한 최신 뉴스 Merus (NASDAQ:MRUS) 주식

Merus

Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.

D-Wave Quantum Inc

Equities

Mid Cap

News

Movers

MRUS

OKLO

QBTS

SBSW

D-웨이브 퀀텀, 어드밴스 오토파츠 등 지난주 급등한 중형주 7종목 (5월 19일~23일)

Merus NV

These mid-cap stocks were the best performers in the last week. Are they in your portfolio?
<ol class="wp-block-list">
<li>D-Wave Quantum Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QBTS#NYSE">QBTS</a>) shares jumped 53.47% after the company announced it launched its Advantage2 quantum system to address problems in optimization, <a href="https://www.benzinga.com//node/45518005" target="_blank" rel="noreferrer noopener">AI, and materials simulation</a>.</li>
<li>Regencell Bioscience Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) stock gained 42.49% last week.</li>
<li>Advance Auto Parts Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AAP#NYSE">AAP</a>) stock increased 38.94%  after the company <a href="https://www.benzinga.com//node/45567507" target="_blank" rel="noreferrer noopener">reported first-quarter results</a>. Several analysts raised the <a href="https://www.benzinga.com/quote/aap/analyst-ratings" target="_blank" rel="noreferrer noopener">price forecast on the stock</a>.</li>
<li>Merus N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) stock rose 32.68% after the company disclosed interim clinical data as of a February 27, 2025, data cutoff from the ongoing phase 2 trial of the bispecific antibody petosemtamab in <a href="https://www.benzinga.com//node/45576972" target="_blank" rel="noreferrer noopener">combination with pembrolizumab</a>.</li>
<li>Oklo Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKLO#NYSE">OKLO</a>) shares upped 29.56%, probably due to reports indicating that Trump will sign executive orders to ease regulatory <a href="https://www.benzinga.com//node/45590362" target="_blank" rel="noreferrer noopener">requirements for new reactors</a>.</li>
<li>Sibanye-Stillwater Limited ADS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SBSW#NYSE">SBSW</a>) shares were up 29.26%.</li>
<li>BGM Group Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BGM#NASDAQ">BGM</a>) stock gained 27.20% last week.</li>
</ol>
Photo via Shutterstock

D-Wave Quantum And Advance Auto Parts Are Among Top 7 Mid-Cap Gainers Last Week (May 19-May 23): Are The Others In Your Portfolio?

Merus N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) shares are trading higher Friday after the company reported promising interim results from its ongoing phase 2 trial evaluating petosemtamab in combination with pembrolizumab for <a href="https://www.benzinga.com/pressreleases/25/05/g45576972/merus-petosemtamab-with-pembrolizumab-interim-data-demonstrates-robust-efficacy-and-durability-in-">head and neck cancer.</a>
What To Know: The data, which will be formally presented at the 2025 ASCO Annual Meeting, showed a 63% overall response rate and a 79% 12-month overall survival rate among 43 evaluable patients with PD-L1+ recurrent/metastatic head and neck squamous cell carcinoma.
The trial also reported a median progression-free survival of nine months, with six patients achieving complete responses and 21 showing partial responses. Importantly, no significant overlapping toxicities were observed in the treatment combination, which was generally well tolerated. Merus noted that 14 responders remained on therapy at the time of the Feb. 27 2025 data cutoff.
Analysts Weigh In: Needham raised its price target on Merus from $75 to $88, stating the updated data meaningfully de-risk the ongoing phase 3 trials. BMO Capital also raised its target from $96 to $110.
Topline data from one or both of the ongoing phase 3 studies are expected in 2026. 
MRUS Price Action: Merus shares were up 34.9% at $56.11 at the time of writing, according to<a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2"> Benzinga Pro.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45592743/stocks-bitcoin-fall-on-trumps-tariff-threats-gold-rallies-whats-driving-markets-friday">Stocks, Bitcoin Fall On Trump&#8217;s Tariff Threats, Gold Rallies: What&#8217;s Driving Markets Friday? </a></li>
</ul>
Image Via Shutterstock.

Merus Stock Surges Over 35% On Strong Phase 2 Cancer Trial Results: What's Going On?

WIIM

Merus shares are trading higher after the company reported interim clinical data form the ongoing phase 2 trial of petosemtamab in combination with pembrolizumab. Multiple analysts raised their price targets on the stock.

BMO Capital analyst Evan David Seigerman maintains Merus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) with a Outperform and raises the price target from $96 to $110.

Price Target

Analyst Ratings

BMO Capital Maintains Outperform on Merus, Raises Price Target to $110

U.S. stocks were lower, with the Dow Jones index falling around 300 points on Friday.
Shares of Frontline plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FRO#NYSE">FRO</a>) rose during Friday's session <a href="https://www.benzinga.com/quote/FRO/earnings">following first-quarter results</a>.
The company reported revenue of $427.9 million, surpassing the $264.2 million consensus. Adjusted EPS declined to 18 cents from 62 cents a year ago, missing the consensus of 23 cents.
Frontline shares gained 3.7% to $17.81 on Friday.
Here are some other big stocks recording gains in today&#8217;s session.
<ul class="wp-block-list">
<li>Merus N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) shares jumped 30% to $54.04 as the company disclosed interim clinical data as of a February 27, 2025 data cutoff from the ongoing phase 2 trial of the bispecific antibody petosemtamab in combination with pembrolizumab.</li>
<li>NANO Nuclear Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NNE#NASDAQ">NNE</a>) rose 24.7% to $34.40.</li>
<li>Centrus Energy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEU#NYSE">LEU</a>) gained 23.4% to $114.98.</li>
<li>Oklo Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKLO#NYSE">OKLO</a>) rose 23.1% to $49.03 after Wedbush raised its price target on the stock from $45 to $55 and maintained an Outperform rating.</li>
<li>Centrus Energy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEU#NYSE">LEU</a>) gained 23.1% to $114.80.</li>
<li>Uranium Energy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UEC#NYSE">UEC</a>) gained 19.2% to $6.15.</li>
<li>NuScale Power Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMR#NYSE">SMR</a>) shares gained 16% to $29.36.</li>
<li>NexGen Energy Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NXE#NYSE">NXE</a>) rose 11.6% to $6.07.</li>
<li>Intuit Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTU#NASDAQ">INTU</a>) gained 8.8% to $724.54 after the company reported better-than-expected third-quarter financial results and raised guidance.</li>
<li>Cameco Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCJ#NYSE">CCJ</a>) rose 8.2% to $57.13.</li>
<li>BWX Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BWXT#NYSE">BWXT</a>) gained 6.5% to $114.70.</li>
<li>Fluor Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLR#NYSE">FLR</a>) rose 5.4% to $39.61.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/05/45585296/jim-cramer-says-medical-properties-trust-has-too-much-risk-likes-this-industrial-stock">Jim Cramer Says Medical Properties Trust Has &#8216;Too Much Risk,&#8217; Likes This Industrial Stock</a> </li>
</ul>
Photo via Shutterstock

Intraday Update

Markets

Trading Ideas

BWXT

INTU

Nuveen Arizona Dividend Advantage Municipal Funds 3

Frontline, Merus, Intuit And Other Big Stocks Moving Higher On Friday

Merus shares are trading higher after Needham raised its price target on the stock from $75 to $88.

Needham analyst Ami Fadia maintains Merus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) with a Buy and raises the price target from $75 to $88.

Needham Maintains Buy on Merus, Raises Price Target to $88

-&nbsp; 63% response rate observed among 43 evaluable patients
-&nbsp; 79% overall survival rate at 12-months; 9 months median progression-free survival
-&nbsp; Conference Call on Thursday, May 22 at 5:30 p.m. ET &nbsp;
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=9FhYyVwI9DsnInrbxOt--inJgjOKfmMbph8kfn71rg_QOcr1YnuZK2hzrUydrWlBOD1YgWDc-HEZ2Du9ltkH1g==">Merus N.V.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) (Merus, the Company, we, or our), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics&#xAE;, Triclonics&#xAE; and ADClonics&#xAE;), today announced interim clinical data as of a February 27, 2025 data cutoff from the ongoing phase 2 trial of the bispecific antibody petosemtamab in combination with pembrolizumab. These data will be presented by Dr. Carla M. L. van Herpen M.D. Ph.D., Radboud University Medical Center, Nijmegen, Netherlands at the 2025 American Society of Clinical Oncology&#xAE; (ASCO&#xAE;) Annual Meeting on Monday, June 2 at 9 a.m. - 12:00 p.m. CT.

Biotech

General

Merus Reports Interim Phase 2 Data Showing 63% Response Rate And 79% 12-Month Overall Survival For Petosemtamab Plus Pembrolizumab In Ongoing Trial, To Be Presented At ASCO 2025 With Conference Call Scheduled For May 22

Needham analyst Ami Fadia reiterates Merus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) with a Buy and maintains $75 price target.

Reiteration

Needham Reiterates Buy on Merus, Maintains $75 Price Target

<a href="https://www.globenewswire.com/Tracker?data=1Cv5vc6xPugdycgEI5g5MdjtOphqPViQBh2de9Wew2xQaCN7hVFga3quhCMOlC-V5wWvMzxJvQZavTaoOXF6bg==">Merus N.V.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) ("Merus", "the Company", "we", or "our"), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics&#xAE;, Triclonics&#xAE; and ADClonics&#xAE;), today announced publication on the mechanism of action of petosemtamab, a bispecific antibody targeting Epidermal Growth Factor Receptor (EGFR) and Leucine-Rich G (LGR5), in the scientific journal "Cancers", a MDPI publication, available <a href="https://www.globenewswire.com/Tracker?data=qDy227Jlbf1q1FH5Gxy-pD1yN8G32hMajPBa7ZAAO61n2po-XuClGyspYfkeqMv_Yt_DqAC3_Jcym2YqyszV_3-VsruA190TW6MqqQ6agkc=">here</a>.

Merus Announces Publication On Mechanism Of Action Of Petosemtamab, Bispecific Antibody Targeting EGFR And LGR5, In Scientific Journal "Cancers"

Wells Fargo analyst Eva Fortea Verdejo maintains Merus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) with a Overweight and lowers the price target from $91 to $89.

Wells Fargo Maintains Overweight on Merus, Lowers Price Target to $89

Merus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) reported quarterly losses of $(1.40) per share which missed the analyst consensus estimate of $(1.10) by 27.27 percent. This is a 137.29 percent decrease over losses of $(0.59) per share from the same period last year. The company reported quarterly sales of $26.49 million which beat the analyst consensus estimate of $7.82 million by 238.85 percent. This is a 235.76 percent increase over sales of $7.89 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Merus Q1 EPS $(1.40) Misses $(1.10) Estimate, Sales $26.49M Beat $7.82M Estimate

- Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC interim clinical data selected for poster presentation &nbsp;
- Conference call on&nbsp;Thursday, May 22&nbsp;at&nbsp;5:30 p.m. ET&nbsp;to discuss full ASCO&#xAE;&nbsp;data set
UTRECHT, The Netherlands&nbsp;and&nbsp;CAMBRIDGE, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=yI2ecVsdRdXGdF2kI9WTwgqSchuYceNZul-sZuLiDMAEyEDBbIn5uDoCY8xIDJxN6qJWid8zPIakPcw51WnyrA==">Merus</a> N.V.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) (Merus, the Company, we, or our), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics&#xAE;, Triclonics&#xAE;&nbsp;and ADClonics&#xAE;), today announced the acceptance of an abstract for presentation at the 2025&nbsp;American Society of Clinical Oncology&#xAE;&nbsp;(ASCO&#xAE;) Annual Meeting, being held in&nbsp;Chicago, Illinois&nbsp;on&nbsp;May 30- June 3, 2025.
An updated analysis of the interim clinical data from the phase 2 trial of petosemtamab with pembrolizumab as 1L treatment of PD-L1+ recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC) will be presented in a poster at 2025 ASCO&#xAE;. The presentation will include data on the entire 45 patient dataset and follows the early clinical efficacy and encouraging safety data previously presented at 2024 ASCO&#xAE;.

Merus Says Petosemtamab In Combination With Pembrolizumab In 1L PD-L1+ R/M HNSCC Interim Clinical Data Selected For Poster Presentation At 2025 ASCO Annual Meeting

Needham analyst Ami Fadia reiterates Merus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) with a Buy and maintains $83 price target.

Needham Reiterates Buy on Merus, Maintains $83 Price Target

Guggenheim analyst Michael Schmidt reiterates Merus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) with a Buy and maintains $109 price target.

Guggenheim Reiterates Buy on Merus, Maintains $109 Price Target

B of A Securities analyst Tazeen Ahmad maintains Merus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) with a Buy and lowers the price target from $73 to $70.

B of A Securities Maintains Buy on Merus, Lowers Price Target to $70

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Merus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) with a Buy and maintains $85 price target.

HC Wainwright & Co. Reiterates Buy on Merus, Maintains $85 Price Target

Needham analyst Ami Fadia maintains Merus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) with a Buy and lowers the price target from $85 to $83.

Needham Maintains Buy on Merus, Lowers Price Target to $83

Merus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) reported quarterly losses of $(3.35) per share which beat the analyst consensus estimate of $(3.80) by 11.84 percent. The company reported quarterly sales of $36.133 which missed the analyst consensus estimate of $38.544 million by 100.00 percent.

Merus FY 2024 GAAP EPS $(3.35) Beats $(3.80) Estimate, Sales $36.133 Miss $38.544M Estimate

Health Care

Press Releases

Petosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD-L1 positive head and neck squamous cell carcinoma

Merus to Present at Upcoming Investor Conferences

Merus Announces Financial Results for the Fourth Quarter and Full Year 2024 and Provides Business Update

Merus to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference

Merus Announces Abstract Accepted for Presentation at the 2025 ASCO® Annual Meeting

Merus Announces Financial Results for the First Quarter 2025 and Provides Business Update

Merus to Present at BofA Securities 2025 Health Care Conference

Merus Announces the Journal Publication of Petosemtamab Mechanism of Action

Merus' Petosemtamab with Pembrolizumab Interim Data Demonstrates Robust Efficacy and Durability in 1L PD-L1+ r/m HNSCC

BMO Capital

Needham

Wells Fargo

Guggenheim

B of A Securities

지난주 최고의 성과를 올린 중형주는 다음과 같다.
<ol class="wp-block-list">
<li>D-웨이브 퀀텀(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QBTS#NYSE">QBTS</a>) 주가는 53.47% 급등했다. 회사가 <a href="https://www.benzinga.com//node/45518005" target="_blank" rel="noreferrer noopener">최적화, AI, 및 재료 시뮬레이션</a> 문제를 해결하기 위해 어드밴티지 2(Advantage2) 양자 시스템을 출시했다고 발표했다.</li>
<li>리젠셀 바이오사이언스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) 주가는 지난 주 42.49% 상승했다.</li>
<li>어드밴스 오토파츠(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AAP#NYSE">AAP</a>) 주가는 38.94% 증가했다. 회사가 <a href="https://www.benzinga.com//node/45567507" target="_blank" rel="noreferrer noopener">1분기 실적을 발표</a>한 후 여러 애널리스트들이 <a href="https://www.benzinga.com/quote/aap/analyst-ratings" target="_blank" rel="noreferrer noopener">목표주가를 상향 조정</a>했다.</li>
<li>메루스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) 주가는 32.68% 상승했다. 회사는 <a href="https://www.benzinga.com//node/45576972">펨브롤리주맙(Pembrolizumab) 병용</a>하는 이중특이적 항체 페토셈타맙(petosemtamab)의 진행 중인 임상 2상 시험에서 2025년 2월 27일 데이터 컷오프 기준 중간 임상 데이터를 공개한 후 32.68% 상승했다.</li>
<li>오클로(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKLO#NYSE">OKLO</a>) 주가는 29.56% 상승했다. 이는 아마도 트럼프가 새로운 원자로에 대한 규제 <a href="https://www.benzinga.com//node/45590362" target="_blank" rel="noreferrer noopener">요건을 완화하는 행정명령을 서명할 것이라는 보도</a> 때문인 것으로 보인다.</li>
<li>시바니 스틸워터(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SBSW#NYSE">SBSW</a>) 주가는 29.26% 상승했다.</li>
<li>BGM그룹(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BGM#NASDAQ">BGM</a>) 주가는 지난 주 27.20% 상승했다.</li>
</ol>
사진 출처: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 수익률을 높이세요.
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Merus

뉴스

에 대한 최신 뉴스 Merus (NASDAQ:MRUS) 주식

일요일, 5월 25, 2025

뉴스

파트너 / 기고자

벤징가 글로벌